Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials

被引：0
|
作者：
Run-Cong Nie
Xue-Bin Zou
Shu-Qiang Yuan
Ying-Bo Chen
Shi Chen
Yong-Ming Chen
Guo-Ming Chen
Xiao-Jiang Chen
Tian-Qi Luo
Shu-Man Li
Jin-Ling Duan
Yun Wang
Yuan-Fang Li
机构：
[1] Sun Yat-sen University Cancer Center,Department of Gastric Surgery
[2] State Key Laboratory of Oncology in South China,Department of Ultrasound, Sun Yat
[3] Collaborative Innovation Center for Cancer Medicine,sen University Cancer Center, State Key Laboratory of Oncology in South China
[4] Collaborative Innovation Center for Cancer Medicine,Department of Gastric Surgery, The 6th Affiliated Hospital
[5] Sun Yat-sen University,Department of Experimental Research (Cancer Institute)
[6] Sun Yat-sen University Cancer Center,Department of Hematologic Oncology, Sun Yat
[7] State Key Laboratory of Oncology in South China,sen University Cancer Center, State Key Laboratory of Oncology in South China
[8] Collaborative Innovation Center for Cancer Medicine,undefined
[9] Collaborative Innovation Center for Cancer Medicine,undefined
来源：
BMC Cancer | / 20卷
关键词：
Pancreatic cancer; Disease-free survival; Overall survival; Surrogate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] End points for adjuvant therapy trials: Has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill, Sharlene
    Sargent, Daniel
    ONCOLOGIST, 2006, 11 (06): : 624 - 629
  • [32] Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials
    Makris, Eleftherios A.
    MacBarb, Regina
    Harvey, Danielle J.
    Poultsides, George A.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (08) : 2371 - 2378
  • [33] RECURRENCE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADULTS WITH EARLY-STAGE HEPATOCELLULAR CARCINOMA (HCC): A CORRELATION META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)
    Leung, L.
    Singh, P.
    Ademisoye, E.
    Hofer, K.
    Qian, A.
    kim, I
    VALUE IN HEALTH, 2023, 26 (06) : S44 - S44
  • [34] Disease free survival as surrogate end-point for overall survival in adjuvant taxane-based chemotherapy for breast cancer: Analysis of randomized clinical trials
    Ciccarese, M.
    Bria, E.
    Cuppone, F.
    Nistico, C.
    Carlini, P.
    Natoli, G.
    Nuzzo, C.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    ANNALS OF ONCOLOGY, 2006, 17 : XI15 - XI15
  • [35] Disease-free survival as a surrogate endpoint for overall survival in adults with early-stage pancreatic cancer: A trial-level surrogacy analysis.
    da Silva, Luis Felipe Leite
    Almeida, Luiz F. Costa
    Noronha, Mariana Macambira
    da Conceicao, Lucas Diniz
    Belotto, Marcos
    Megid, Thais Baccili Cury
    Peixoto, Renata D'Alpino
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 708 - 708
  • [36] Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy
    Cabrit, Nicolas
    Cheugoua-Zanetsie, Maurice
    Tierney, Jayne
    Thirion, Pierre
    Nankivell, Matthew
    Winter, Kathryn
    Yang, Hong
    Wijnhoven, Bas
    Vernerey, Dewi
    Smithers, B. Mark
    Piessen, Guillaume
    Nilsson, Magnus
    Boonstra, Jurjen
    Ychou, Marc
    Law, Simon
    Cunningham, David
    de Vathaire, Florent
    Stahl, Michael
    Urba, Susan
    Valmasoni, Michele
    Williaume, Daniele
    Thomas, Janine
    Lordick, Florian
    Tepper, Joel
    Gebski, Val
    Burmeister, Bryan
    Paoletti, Xavier
    van Sandick, Johanna
    Fu, Jianhua
    Pignon, Jean-Pierre
    Ducreux, Michel
    Faron, Matthieu
    Michiels, Stefan
    EUROPEAN JOURNAL OF CANCER, 2025, 218
  • [37] Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis (vol 20, pg 361, 2019)
    Saad, E. D.
    Squifflet, P.
    Burzykowski, T.
    LANCET ONCOLOGY, 2019, 20 (03): : E132 - E132
  • [38] Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials
    Uson, P. L. S.
    Silva, D. Dias e
    de Castro, N. M.
    da Silva Victor, E.
    Rother, E. T.
    Araujo, S. E. A.
    Borad, M. J.
    Moura, F.
    ESMO OPEN, 2023, 8 (01)
  • [39] Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials
    Chen, Yu-Pei
    Sun, Ying
    Chen, Lei
    Mao, Yan-Ping
    Tang, Ling-Long
    Li, Wen-Fei
    Liu, Xu
    Zhang, Wen-Na
    Zhou, Guan-Qun
    Guo, Rui
    Lin, Ai-Hua
    Ma, Jun
    RADIOTHERAPY AND ONCOLOGY, 2015, 116 (02) : 157 - 166
  • [40] Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
    Han, Kelong
    Ren, Melanie
    Wick, Wolfgang
    Abrey, Lauren
    Das, Asha
    Jin, Jin
    Reardon, David A.
    NEURO-ONCOLOGY, 2015, 17 (05) : 764 - 765
12345